Brentuximab vedotin: clinical updates and practical guidance
Blood Research
; : 243-253, 2017.
Article
em En
| WPRIM
| ID: wpr-21834
Biblioteca responsável:
WPRO
ABSTRACT
Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. Owing to the remarkable efficacy shown in CD30-positive lymphomas, such as Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, BV was granted accelerated approval in 2011 by the US Food and Drug Administration. Thereafter, many large-scale trials in various situations have been performed, which led to extensions of the original indication. The aim of this review was to describe the latest updates on clinical trials of BV and the in-practice guidance for the use of BV.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
United States Food and Drug Administration
/
Doença de Hodgkin
/
Linfoma Anaplásico de Células Grandes
/
Antígeno Ki-1
/
Organização do Financiamento
/
Linfoma
Tipo de estudo:
Guideline
Idioma:
En
Revista:
Blood Research
Ano de publicação:
2017
Tipo de documento:
Article